Sign in
Taking people in United StatesPhase 3

Center or home exercise and beetroot juice for peripheral artery disease

Tests walking exercise and beetroot juice in peripheral artery disease.

Key facts

Who runs it
Northwestern University
Where
Chicago and Minneapolis, United StatesSee the 3 sites
Trial code
Registry title
SMART Exercise for PAD
Status
Recruiting
Phase
Phase 3
People taking part
210 people, planned
Started
8 Sept 2023
Expected to end
31 Mar 2029
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Supervised Treadmill Exercise
  • Home-Based Exercise
  • Nitrate-rich beetroot Juice
Record updated
15 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 and older with peripheral artery disease (PAD), narrowed leg arteries. It tests supervised or home walking exercise with nitrate-rich beetroot juice or a placebo drink.

Age
50 Years and older
Sex
All sexes
Disease stage
PAD shown by an ABI <= 0.90, or vascular lab tests (toe brachial pressure <= 0.70), or at least 70% narrowing of a leg artery on imaging, or an ABI >0.90 and <1.00 with a 20% or greater drop after a heel-rise test.
Earlier treatment
No supervised treadmill exercise or cardiac rehabilitation in the previous three months. No major surgery, heart or leg artery procedure in the previous three months. Not already exercising at the study's level.
Biomarker or test result
Ankle brachial index (ABI) as described. Cannot join with eGFR <30 or potassium >5.0.

Main reasons for not taking part

  • Leg amputation, foot ulcer on the bottom of the foot, or severe leg blood flow loss (ABI <0.40 with rest pain)
  • Using a wheelchair or walker, or walking limited by something other than PAD
  • Kidney disease needing dialysis, or kidney stones needing low oxalate intake
  • Unwilling to drink beetroot juice, beetroot allergy, or already taking beetroot or nitrate supplements
  • Unstable angina, dementia, or not speaking English

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as either:
  • An ABI <= 0.90 at baseline
  • Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities
  • An ABI of >0.90 and <1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test

Who cannot take part

  • Planned major surgery, coronary or leg revascularization during the next six months
  • Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  • Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  • Currently consuming beetroot juice or oral nitrate or nitrite, or a beetroot supplement, and/or unwilling to avoid these during study participation. Participants currently consuming one cup of beets daily will be asked to discontinue beet ingestion for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more, they will not be eligible for the clinical trial
  • Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice
  • Participation in a supervised treadmill exercise program or cardiac rehabilitation program in previous three months
  • Walking is limited by a condition other than PAD
  • Current foot ulcer on bottom of foot
  • End-stage kidney disease (ESKD) associated with the need for dialysis
  • Mini-Mental Status Examination (MMSE) score < 23 or dementia. However, if the MMSE is < 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE < 23 to participate, as appropriate
  • Allergy to beetroot juice
  • Unstable angina
  • Visual impairment that limits walking ability
  • History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial
  • Abnormal baseline stress test without subsequent clearance for exercise by physician
  • An eGFR value <30 or potassium >5.0
  • Above- or below-knee amputation
  • Limb-threatening ischemia defined as an ABI <0.40 with symptoms of rest pain
  • Wheelchair confinement or requiring a walker to ambulate
  • Unwilling to drink beetroot juice
  • Unwilling to accept randomization into either group (home based exercise or supervised exercise)
  • Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial
  • Already exercising at a level consistent with exercise intervention
  • Non-English speaking. The SMART PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages, nor does it have the ability to translate all study materials into other languages
  • Baseline blood pressure <100/45
  • Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue
  • In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United StatesContact: Kathryn Domanchuk, BSTaking people
  • University of ChicagoChicago, United StatesContact: Tamar Polonsky, MDTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Diane Treat-Jacobson, PhDTaking people

About the trial

What the trial wants to find out

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. Walking exercise is first line therapy to improve walking distance for PAD, but it does not eliminate ischemic leg symptoms in most people with PAD. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. The investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. Participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

The 4 groups in the trial

  • Supervised treadmill exercise + nitrate rich beetroot juiceTreatment being tested

    This group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.

    Treatment: Supervised Treadmill Exercise and Nitrate-rich beetroot Juice

  • Supervised treadmill exercise + placeboPlacebo, for comparison

    This group will be participating in Supervised Treadmill Exercise and drinking placebo beetroot juice with nitrate removed for 12 weeks.

    Treatment: Supervised Treadmill Exercise

  • Home-based walking exercise + nitrate rich beetroot juiceTreatment being tested

    This group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.

    Treatment: Home-Based Exercise and Nitrate-rich beetroot Juice

  • Home-based walking exercise + placeboPlacebo, for comparison

    This group will be participating in Home-Based Exercise and drinking placebo beetroot juice with nitrated removed for 12 weeks.

    Treatment: Home-Based Exercise

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for Peripheral Artery Disease: The SMART PAD Trial
Plain-language title
Center or home exercise and beetroot juice for peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
15 April 2026
SMART Exercise for PAD (NCT06032065) – Frontlight Research